Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.33    -0.01 (-0.43%)
Bid:
2.33
Ask:
2.35
Spread: 0.02 (0.858%)
Market Cap: $752.76m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Director/PDMR Shareholding

23 Dec 2020 09:07

RNS Number : 6607J
RTW Venture Fund Limited
23 December 2020
 

RTW VENTURE FUND LIMITED

(the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED ("PCA") WITH THEM

The Company has been notified that Stephanie Anne Sirota Revocable Trust, a PCA of Stephanie Sirota, has transferred 169,000 Ordinary Shares in the Company to SAS Family Holdings LLC, an LLC owned 100% by SAS 2020 Family Trust.

 

The underlying beneficial owner is a PCA of Stephanie Sirota.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Stephanie Anne Sirota Revocable Trust re Stephanie Sirota

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Stephanie Sirota

Director of RTW Venture Fund Limited

 

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

RTW Venture Fund Limited

b)

 

LEI

 

 

549300Q7EXQQH6KF7Z84

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of no par value

 

 

GG00BKTRRM22

 

 

b)

 

Nature of the transaction

 

 

 

Transfer of shares for nil consideration from Stephanie Anne Sirota Revocable Trust to SAS Family Holdings LLC, an LLC owned 100% by SAS 2020 Family Trust.

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

For nil consideration.

 

169,000

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

- Price

 

- Principal amount

 

 

 

 

169,000

 

For nil consideration

 

For nil consideration

e)

 

Date of the transaction

 

 

18 November 2020

f)

 

Place of the transaction

 

 

London Stock Exchange, Specialist Fund Segment

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCBDDUGDDGGX
Date   Source Headline
13th Mar 20267:01 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSMonthly Valuation Update and Factsheet
13th Mar 20267:00 amRNSMonthly Valuation Update and Factsheet
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSMonthly Valuation Update and Factsheet
23rd Jan 20267:00 amRNSCorxel completes $287 million Series D-1 financing
22nd Jan 202610:00 amRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSGSK to acquire RAPT Therapeutics
16th Jan 20267:00 amRNSBoston Scientific to acquire Penumbra
15th Jan 20267:00 amRNSMonthly Valuation Update and Factsheet
12th Jan 20267:00 amRNSAktis announces $318 million IPO
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
18th Dec 20257:00 amRNSNew investment in Yarrow Bioscience
12th Dec 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSInclusion in FTSE 250 Index
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20256:00 pmRNSSpectris
1st Dec 20257:00 amRNSTotal Voting Rights
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20252:30 pmRNSTransaction in Own Shares
25th Nov 202512:00 pmRNSRetail Investor Webinar
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSMonthly Valuation Update and Factsheet
7th Nov 20257:00 amRNSEvommune announces $150 million IPO
5th Nov 202510:00 amRNSHolding(s) in Company
3rd Nov 20259:33 amRNSTotal Voting Rights
31st Oct 20257:00 amRNSRoyalty Funding Agreement with Savara Inc.
29th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSNovartis to acquire Avidity Biosciences
20th Oct 20257:00 amRNSCapital Allocation Plan based on M&A successes
15th Oct 20257:00 amRNSKailera Therapeutics announces Series B financing
14th Oct 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Oct 20257:00 amRNSNovo Nordisk to acquire Akero Therapeutics
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20257:01 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSGenmab to acquire Merus
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:01 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSBiogen to acquire Alcyone Therapeutics
15th Sep 20257:00 amRNSMonthly Valuation Update and Factsheet
11th Sep 20257:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.